Search
START Publications 2017

1. Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial. J O'Connor, MJ Vjecha, AN Phillips, B Angus, D Cooper, B Grinsztejn, G Lopardo, S Das, R Wood, A Wilkin, H Klinker, P Kantipong, KL Klingman, D Jilich, E Herieka, E Denning, I Abubakar, F Gordin, JD Lundgren; INSIGHT START study group.
Lancet HIV. 2017 Jan 4. pii: S2352-3018(16)30216-8. Abstract

2 Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV-Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) Trial. JV Baker, S Sharma, AC Achhra, JI Bernardino, JR Bogner,  D Duprez, S Emery, B Gazzard, J Gordin, G Grandits, AN Phillips, S Schwarze, EZ Soliman, SA Spector, G Tambussi, J Lundgren; INSIGHT (International Network for Strategic Initiatives in Global HIV Trials) START (Strategic Timing of Antiretroviral Treatment) Study Group.
Journal of the American Heart Association 2017; 6(5). Abstract 

3 Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial. JF Hoy, B Grund, M Roediger, AV Schwartz, J Shepherd, A Avihingsanon, S Badal-Faesen, S de Wit, S Jacoby , A La Rosa, S Pujari, M Schechter, D White, NW Engen, K Ensrud, PD Aagaard, Carr A14; INSIGHT START Bone Mineral Density Substudy Group.
Journal of Bone and Mineral Research 2017.  [Epub ahead of print] Abstract

4The per-protocol effect of immediate versus deferred antiretroviral therapy initiation. S Lodi, S Sharma, JD Lundgren, AN Phillips, SR Cole, R Logan, BK Agan, A Babiker, H Klinker, H Chu, M Law, JD Neaton, MA Hernán; INSIGHT Strategic Timing of AntiRetroviral Treatment (START) study group.
AIDS. 2016;30(17):2659-2663. Abstract